The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.
Each proposed U54 Partnership Center must be based on a collaboration between a research institution in the United States (as the applicant institution) and partnering institution(s) in low- and middle-income countries (LMICs) in the LAC region. The proposed clinical trials should be focused on optimizing clinical prevention interventions among HIV-infected individuals, including immunoprevention (vaccination), screening and triage, and precancer treatment.
Each Partnership Center application must propose a Clinical Trials Program that will develop and conduct three prevention clinical trials within the 5-year project period. As infrastructure supporting the Clinical Trials Program, each Partnership Center should include an Administrative and Coordinating Core, a Data Management and Statistical Core, and a Central Laboratory Core. Results of the clinical trials conducted through the Partnership Centers are expected to influence the development of clinical practice guidelines to improve preventive clinical care and reduce the burden of highly preventable HPV-related cancers in HIV-infected individuals.
The Clinical Trials Program of each Partnership Center is expected to develop and conduct three clinical trials that are expected to focus on one or more of the following three broad prevention science areas:
Area 1: HPV immunoprevention among HIV-infected individuals;
Area 2: Cervical cancer screening and triage approaches for HIV-infected women; and
Area 3: Evaluating non-surgical strategies for treating HPV-related precancerous lesions among HIV-infected individuals.
University is limited to one proposal.
|UIC Letter of Intent||
September 14, 2018
|UIC Internal Competition||
|Sponsor Letter of Intent||
November 15, 2018
Letter of Intent
Depending upon the number of LOIs submitted, OVCR might be required to facilitate an internal peer review process to select UIC’s submission(s) to this program. White paper instructions will distributed to those who have submitted LOIs.
DEADLINES FOR LOIs and WHITE PAPERS ARE 12:00 PM (NOON) CHICAGO TIME
Please contact RDS at RDS@uic.edu or 312-996-9969 with any questions.
If an authorized principal investigator is not listed above, please consider the limited competition still open. Contact RDS@uic.edu for further information.